|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Sanofi-Aventis
gptkb:Ariad_Pharmaceuticals
gptkb:Medi_Gene_AG
|
|
gptkbp:acquisition
|
gptkb:Chattem,_Inc.
gptkb:Boehringer_Ingelheim's_animal_health_business
gptkb:Genzyme_Corporation
|
|
gptkbp:ceo
|
gptkb:Paul_Hudson
|
|
gptkbp:clinical_trial
|
ongoing
investing in innovative therapies
|
|
gptkbp:collaborations
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:employees
|
around 100,000
|
|
gptkbp:founded
|
gptkb:2004
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:headquarters
|
gptkb:Paris,_France
|
|
gptkbp:healthcare
|
prescription drugs
over-the-counter products
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi S. A.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:market_cap
|
approximately €100 billion (2021)
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly
gptkb:temple
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Regeneron
gptkb:Novartis
GSK for COVID-19 vaccine
|
|
gptkbp:products
|
vaccines
diabetes treatments
cardiovascular medications
|
|
gptkbp:research
|
gptkb:John_Francis_Reed
|
|
gptkbp:research_focus
|
neurology
oncology
rare diseases
immunology
|
|
gptkbp:revenue
|
€36.1 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:Euronext_Paris
|
|
gptkbp:subsidiary
|
gptkb:Sanofi_Genzyme
gptkb:Sanofi_Pasteur
|
|
gptkbp:sustainability_initiatives
|
diversity and inclusion
environmental responsibility
access to medicines
|
|
gptkbp:symbol
|
gptkb:SAN
|
|
gptkbp:website
|
www.sanofi.com
|